Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Faricimab in AMD Patients With SHRM and Type 2/Mixed MNV
NCT07403825Phase 4Recruiting
- Sponsor
- Biobizkaia Health Research Institute
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of faricimab in Age-related macular degeneration (AMD), sponsored by Biobizkaia Health Research Institute. Started May 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
Age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT07403825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403825.